- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT05607004
(Z)-Endoxifen for the Treatment of Premenopausal Women With ER+/HER2- Breast Cancer (EVANGELINE)
A Randomized Phase 2 Non-inferiority Trial of (Z)-Endoxifen and Exemestane + Goserelin as Neoadjuvant Treatment in Premenopausal Women With ER+/HER2- Breast Cancer
This open-label research study is studying (Z)-endoxifen as a possible treatment for pre-menopausal (still having periods) women with ER+/HER2- breast cancer. (Z)-endoxifen is a selective estrogen receptor modulator or "SERM." SERMs work to treat cancer by blocking the body's natural estrogen from binding to cancer cells. This study includes a pharmacokinetic part (PK, how the drug works in your body) and a treatment part. The primary purpose of the study is to see how (Z)-endoxifen works on tumor cell growth by monitoring a cancer marker called Ki-67. Ki-67 will be measured by biopsy of the breast after about 4 weeks of treatment. If your cancer is responding to treatment based on the Ki-67 results, you may continue treatment up to 24 weeks or until surgery.
The PK part of the study will be enrolled first, enrolling about 18 study participants who will all receive oral once daily (Z)-endoxifen treatment. 12 of these participants will be randomly assigned to treatment with an equal (50/50) chance to be assigned to (Z)-endoxifen or (Z)-endoxifen + goserelin (a medication given to block the ovaries from making estrogen and is also called ovarian suppression). This part of the study will help select the dose of (Z)-endoxifen to use in the treatment part by measuring the levels of (Z)-endoxifen in the blood stream and determine how long it takes for the body to remove it.
About 160 study participants will be enrolled in the treatment part. The treatment part will help to determine how oral once daily (Z)-endoxifen, when taken by itself, compares to oral once daily exemestane (a medication that decreases the amount of estrogen in the body, also known as an aromatase inhibitor) and monthly injections of goserelin. Exemestane and goserelin taken together is a standard treatment regimen for premenopausal patients with ER+/HER2- breast cancer. Study participants are randomly assigned to treatment with an equal (50/50) chance to be assigned to (Z)-endoxifen or standard treatment.
Study participation is up to 24 weeks of treatment followed by surgery.
Study Overview
Status
Conditions
Intervention / Treatment
Study Type
Enrollment (Estimated)
Phase
- Phase 2
Contacts and Locations
Study Contact
- Name: Arezoo Mirad, MD, MS
- Phone Number: 650-647-4913
- Email: Arezoo.Mirad@Atossainc.com
Study Locations
-
-
Arizona
-
Phoenix, Arizona, United States, 85054
- Recruiting
- Mayo Clinic Arizona
-
Principal Investigator:
- Lida Mina, MD
-
Tucson, Arizona, United States, 85719
- Recruiting
- University of Arizona
-
Principal Investigator:
- Sima Ehsani, MD
-
-
Florida
-
Jacksonville, Florida, United States, 32224
- Recruiting
- Mayo Clinic Florida
-
Principal Investigator:
- Pooja Advani, MD
-
-
Kentucky
-
Edgewood, Kentucky, United States, 41017
- Recruiting
- St. Elizabeth Healthcare
-
Principal Investigator:
- Daniel Flora, MD
-
-
Minnesota
-
Rochester, Minnesota, United States, 55905
- Recruiting
- Mayo Clinic Rochester
-
Principal Investigator:
- Matthew Goetz, MD
-
-
Missouri
-
Saint Louis, Missouri, United States, 63110
- Recruiting
- Washington University School of Medicine
-
Principal Investigator:
- Nusayba Bagegni, MD
-
-
South Dakota
-
Sioux Falls, South Dakota, United States, 57105
- Recruiting
- Avera Cancer Institute
-
Principal Investigator:
- Jason Jones, MD
-
-
Texas
-
Webster, Texas, United States, 77598
- Withdrawn
- Tranquility Research
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- Premenopausal women 18 years or older
- Not lactating, pregnant, or planning to become pregnant in the next year
- Agree to use at least one non-hormonal highly effective method of contraception for the entire duration of study participation.
- ER+/HER2-: [ER] ≥ 67% or Allred Score 6-8) / HER2- (histologically confirmed) using American Society of Clinical Oncology (ASCO)/College of American Pathologists (CAP) guidelines
- Clinical T2 or T3 and N0 or N1 invasive breast cancer (per American Joint Committee on Cancer [AJCC] 8th edition clinical staging)
- Nottingham Grade 1 or 2
- ECOG Performance Status (ECOG PS) of 0 to 2
Exclusion Criteria:
- Inflammatory breast cancer; bilateral disease (DCIS/LCIS in contralateral breast OK)
- Prior diagnosis or treatment for breast cancer, including carcinoma in situ, or history of any other active malignancy within the past 2 years prior to study entry
- Uncontrolled intercurrent illness including, but not limited to:
- Ongoing or active infection requiring systemic treatment with strong inhibitors/inducers of CYP450 enzymes (including bacterial infection, fungal infection, or detectable viral infection).
- Symptomatic congestive heart failure, unstable angina pectoris, uncontrolled symptomatic cardiac arrhythmias
- Uncontrolled hypertension (defined as blood pressure > 160/90 mm Hg)
- Uncontrolled diabetes (Hemoglobin A1c [HbA1c] >7%)
- Marked baseline prolongation of QT/QTc interval (e.g., repeated demonstration of a QTc interval > 470 milliseconds [msec]) using Fridericia's QT correction formula seen ≤ 28 days of registration
- Known cataracts or retinopathy
- History of deep vein thrombosis (DVT)/pulmonary embolism (PE)
- Known activated protein C (APC) resistance, an inherited coagulation disorder
- Creatine clearance < 60 ml/min
- Total bilirubin ≥ 1.5 x upper limit of normal (ULN)
- Aspartate aminotransferase (AST) or alanine amino transferase (ALT) ≥ 2.5 x ULN
- Platelet count (PLT) ≤ 75,000/mm3
- Hemoglobin (Hb) ≤ 10 g/dL
- Hormonal therapies including birth control and hormone replacement therapy during the study or within 1 week of registration; androgen therapy
- Allergy to endoxifen, goserelin, or exemestane or any of their components
- Participation in another investigational clinical trial ≤ 6 months of registration
- Known metastatic disease
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Treatment Cohort Arm 1 Initial Regimen
(Z)-endoxifen capsules orally once daily for 4 weeks. Dose will be based on the results of the PK Cohort. If Ki-67 ≤ 10% at Week 4, continue on this treatment for up to 6 cycles/Week 24. Each cycle is 28 days. If Ki-67 > 10% at Week 4, participant will be offered modified regimen or be withdrawn and go on to surgery. |
(Z)-endoxifen capsules.
Doses of (Z)-endoxifen to be evaluated include 20 mg (two x 10 mg capsules), 40 mg (one 40 mg capsule) and 80 mg (two x 40 mg capsules).
Other Names:
|
Experimental: PK Cohort
(Z)-endoxifen capsules orally once daily for 4 weeks. Initial (Z)-endoxifen dose evaluated will be 40 mg with an option to evaluate 20 mg or 80 mg. The PK Cohort participants may extend treatment based on Ki-67% at Week 4. If Ki-67 ≤ 10% at Week 4, participant will be offered option to continue on this treatment for up to 6 cycles/Week 24. Each cycle is 28 days. If Ki-67 > 10% at Week 4, participant will be withdrawn and go on to surgery. |
(Z)-endoxifen capsules.
Doses of (Z)-endoxifen to be evaluated include 20 mg (two x 10 mg capsules), 40 mg (one 40 mg capsule) and 80 mg (two x 40 mg capsules).
Other Names:
|
Active Comparator: Treatment Cohort Arm 2 Initial Regimen
Exemestane 25 mg orally once daily for 4 weeks + goserelin 3.6 mg by subcutaneous implant approximately every 28 days. If Ki-67 ≤ 10% at Week 4, continue on this treatment for up to 6 cycles/Week 24. Each cycle is 28 days. If Ki-67 > 10% at Week 4, participant will be offered modified regimen or be withdrawn and go on to surgery. |
exemestane tablets 25 mg
Other Names:
goserelin 3.6 mg subcutaneous implant
Other Names:
|
Experimental: Treatment Cohort Arm 1 Modified Regimen
(Z)-endoxifen capsules orally once daily for 4 weeks + goserelin 3.6 mg by subcutaneous implant approximately every 28 days. (Z)-endoxifen dose will be based on the results of the PK Cohort. If Ki-67 ≤ 10% after 4 weeks of modified regimen, continue on this treatment for up to 6 total treatment cycles/Week 24. Each cycle is 28 days. If Ki-67 > 10% after 4 weeks of modified regimen, participant will be withdrawn and go on to surgery. |
goserelin 3.6 mg subcutaneous implant
Other Names:
(Z)-endoxifen capsules.
Doses of (Z)-endoxifen to be evaluated include 20 mg (two x 10 mg capsules), 40 mg (one 40 mg capsule) and 80 mg (two x 40 mg capsules).
Other Names:
|
Experimental: Treatment Cohort Arm 2 Modified Regimen
(Z)-endoxifen capsules orally once daily for 4 weeks + goserelin 3.6 mg by subcutaneous implant approximately every 28 days. (Z)-endoxifen dose will be based on the results of the PK Cohort. If Ki-67 ≤ 10% after 4 weeks of modified regimen, continue on this treatment for up to 6 total treatment cycles/Week 24. Each cycle is 28 days. If Ki-67 > 10% after 4 weeks of modified regimen, participant will be withdrawn and go on to surgery. |
goserelin 3.6 mg subcutaneous implant
Other Names:
(Z)-endoxifen capsules.
Doses of (Z)-endoxifen to be evaluated include 20 mg (two x 10 mg capsules), 40 mg (one 40 mg capsule) and 80 mg (two x 40 mg capsules).
Other Names:
|
Experimental: PK Cohort 80 mg
(Z)-endoxifen 80 mg capsules orally once daily for 4 weeks. The PK Cohort participants may extend treatment based on Ki-67% at Week 4. If Ki-67 ≤ 10% at Week 4, participant will be offered option to continue on this treatment for up to 6 cycles/Week 24. Each cycle is 28 days. If Ki-67 > 10% at Week 4, participant will be withdrawn and go on to surgery. |
(Z)-endoxifen capsules.
Doses of (Z)-endoxifen to be evaluated include 20 mg (two x 10 mg capsules), 40 mg (one 40 mg capsule) and 80 mg (two x 40 mg capsules).
Other Names:
|
Experimental: PK Cohort 80 mg + OFS
(Z)-endoxifen 80 mg capsules orally once daily for 4 weeks + goserelin 3.6 mg by subcutaneous implant approximately every 28 days. The PK Cohort participants may extend treatment based on Ki-67% at Week 4. If Ki-67 ≤ 10% at Week 4, participant will be offered option to continue on this treatment for up to 6 cycles/Week 24. Each cycle is 28 days. If Ki-67 > 10% at Week 4, participant will be withdrawn and go on to surgery. |
goserelin 3.6 mg subcutaneous implant
Other Names:
(Z)-endoxifen capsules.
Doses of (Z)-endoxifen to be evaluated include 20 mg (two x 10 mg capsules), 40 mg (one 40 mg capsule) and 80 mg (two x 40 mg capsules).
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
PK Cohort - (Z)-endoxifen steady-state plasma concentrations
Time Frame: After 4 weeks of treatment
|
(Z)-endoxifen steady-state plasma concentrations (Css) of evaluable subjects who completed at least one cycle of treatment (28 +/- 3 days)
|
After 4 weeks of treatment
|
Treatment Cohort - Endocrine sensitive disease rate based on Ki-67 percent after 4 weeks of treatment
Time Frame: After 4 weeks of treatment
|
Endocrine sensitive disease rate will be estimated as the percentage of subjects whose 4-week tumor biopsy finds Ki-67 less than or equal to 10 percent among evaluable subjects who began protocol treatment
|
After 4 weeks of treatment
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
PK Cohort - Area under the plasma (Z)-endoxifen concentration-time curve from time zero to last measurable concentration
Time Frame: Days 1 and 28
|
Area under the plasma (Z)-endoxifen concentration-time curve from time zero to last measurable concentration (AUC0-24) on Days 1 and 28 of evaluable subjects who completed at least one cycle of treatment (28 +/- 3 days)
|
Days 1 and 28
|
PK Cohort - Area under the plasma (E)-endoxifen concentration-time curve from time zero to last measurable concentration
Time Frame: Days 1 and 28
|
Area under the plasma (E)-endoxifen concentration-time curve from time zero to last measurable concentration (AUC0-24) on Days 1 and 28 of evaluable subjects who completed at least one cycle of treatment (28 +/- 3 days)
|
Days 1 and 28
|
PK Cohort - Accumulation and accumulation half-life
Time Frame: Days 1 and 28
|
Accumulation and accumulation half-life (Day 28 AUC0-24/Day 1 AUC0-24) of evaluable subjects who completed at least one cycle of treatment (28 +/- 3 days)
|
Days 1 and 28
|
PK Cohort - (Z)-endoxifen steady-state clearance
Time Frame: up to 28 days
|
(Z)-endoxifen CLss (steady-state clearance) of evaluable subjects who completed at least one cycle of treatment (28 +/- 3 days)
|
up to 28 days
|
PK Cohort - (E)-endoxifen steady-state clearance
Time Frame: up to 28 days
|
(E)-endoxifen CLss (steady-state clearance) of evaluable subjects who completed at least one cycle of treatment (28 +/- 3 days)
|
up to 28 days
|
PK Cohort - Maximum plasma (Z)-endoxifen concentration
Time Frame: up to 28 days
|
Maximum plasma (Z)-endoxifen concentration (Cmax) of evaluable subjects who completed at least one cycle of treatment (28 +/- 3 days)
|
up to 28 days
|
PK Cohort - Maximum plasma (E)-endoxifen concentration
Time Frame: up to 28 days
|
Maximum plasma (E)-endoxifen concentration (Cmax) of evaluable subjects who completed at least one cycle of treatment (28 +/- 3 days)
|
up to 28 days
|
PK Cohort - Time to plasma (Z)-endoxifen maximum concentration
Time Frame: up to 28 days
|
Time to plasma (Z)-endoxifen maximum concentration (Tmax) of evaluable subjects who completed at least one cycle of treatment (28 +/- 3 days)
|
up to 28 days
|
PK Cohort - Time to plasma (E)-endoxifen maximum concentration
Time Frame: up to 28 days
|
Time to plasma (E)-endoxifen maximum concentration (Tmax) of evaluable subjects who completed at least one cycle of treatment (28 +/- 3 days)
|
up to 28 days
|
PK Cohort - plasma (Z)-endoxifen concentration
Time Frame: Day 1 up to 12 weeks and up to end of treatment or up to 24 weeks.
|
Trough concentrations of (Z)-endoxifen for subjects in the Treatment Extension
|
Day 1 up to 12 weeks and up to end of treatment or up to 24 weeks.
|
PK Cohort - plasma (E)-endoxifen concentration
Time Frame: Day 1 up to 12 weeks and up to end of treatment or up to 24 weeks.
|
Trough concentrations of (Z)-endoxifen for subjects in the Treatment Extension
|
Day 1 up to 12 weeks and up to end of treatment or up to 24 weeks.
|
PK Cohort - Treatment Cohort - Endocrine sensitive disease rate based on Ki-67 percent after 4 weeks of treatment
Time Frame: After 4 weeks of treatment
|
Endocrine sensitive disease rate will be estimated as the percentage of subjects whose 4-week tumor biopsy finds Ki-67 less than or equal to 10 percent among evaluable subjects who began protocol treatment
|
After 4 weeks of treatment
|
Both Cohorts - Incidence of Adverse Events assessed by CTCAE version 5.0
Time Frame: Informed consent up to follow up visit or up to 30 weeks
|
Incidence and severity of adverse events per CTCAE by treatment
|
Informed consent up to follow up visit or up to 30 weeks
|
Both Cohorts - Incidence of Serious Adverse Events assessed by CTCAE version 5.0
Time Frame: Informed consent up to follow up visit or up to 30 weeks
|
Incidence of serious adverse events by treatment
|
Informed consent up to follow up visit or up to 30 weeks
|
Both Cohorts - Incidence of Adverse Events Leading to Discontinuation
Time Frame: Informed consent up to up to end of treatment or up to 24 weeks
|
Incidence of adverse events leading to discontinuation by treatment
|
Informed consent up to up to end of treatment or up to 24 weeks
|
Both Cohorts - Incidence of Dose Reductions
Time Frame: Day 1 up to time of surgery or up to 27 weeks
|
Proportion of patients who required a dose reduction by treatment arm
|
Day 1 up to time of surgery or up to 27 weeks
|
Both Cohorts - Change in estradiol and estrone
Time Frame: Day 1, up to 4 weeks, up to 12 weeks and up to end of treatment or up to 24 weeks.
|
Median percent change in the E1/E2 ratio
|
Day 1, up to 4 weeks, up to 12 weeks and up to end of treatment or up to 24 weeks.
|
Both Cohorts - Percentage of subjects whose serum thymidine kinase 1 (TK1) falls below the detection limit after 4 weeks of treatment
Time Frame: Day 1, up to 4 weeks, up to 12 weeks and up to end of treatment or up to 24 weeks.
|
Percentage of subjects whose serum TK1 falls below the detection limit (< 20 DiviTum units per liter Du/L) after one cycle of treatment among those with detectable serum TK1 levels prior to start of protocol treatment
|
Day 1, up to 4 weeks, up to 12 weeks and up to end of treatment or up to 24 weeks.
|
Treatment Cohort - Radiographic Response Rate in the breast
Time Frame: Baseline Assessment up to 12 weeks and up to end of treatment or up to 24 weeks
|
Radiological response by RECIST 1.1
|
Baseline Assessment up to 12 weeks and up to end of treatment or up to 24 weeks
|
Treatment Cohort - Pathologic Complete Response per American Joint Committee on Cancer staging system at time of surgery
Time Frame: At time of surgery or up to 27 weeks
|
Pathologic Complete Response (pCR) at surgery defined as the absence of residual invasive breast cancer on hematoxylin and eosin evaluation of the resected breast specimen and of all sampled lymph nodes (sentinel ± axillary) removed following completion of neoadjuvant systemic therapy
|
At time of surgery or up to 27 weeks
|
Treatment Cohort - Pre-Operative Endocrine Prognostic Index at time of surgery
Time Frame: At time of surgery or up to 27 weeks
|
Rate of Pre-Operative Endocrine Prognostic Index (PEPI) 0 at time of surgery using residual tumor specimen
|
At time of surgery or up to 27 weeks
|
Treatment Cohort - Residual Cancer Burden at time of surgery
Time Frame: At time of surgery or up to 27 weeks
|
Rate of residual cancer burden class of 0-I at time of surgery
|
At time of surgery or up to 27 weeks
|
Treatment Cohort - Conversion Rate
Time Frame: From baseline to time of surgery or up to 27 weeks
|
Evaluate the conversion rate from breast conservation surgery ineligible to breast conservation surgery eligible.
Evaluation is based on surgeon's impression of the type of surgery participant is eligible for (candidate for lumpectomy, candidate for modified radical mastectomy, inoperable) at baseline compared to surgeon's impression after completion of neoadjuvant treatment
|
From baseline to time of surgery or up to 27 weeks
|
Treatment Cohort - Actual Conversion Rate
Time Frame: At time of surgery or up to 27 weeks
|
Evaluate the actual rate of breast conservation surgery.
Evaluation will be based on the extent of the surgical procedure at the time of surgery (lumpectomy, partial or segmental mastectomy, simple/total mastectomy, skin and/or nipple sparing mastectomy, radical mastectomy or other)
|
At time of surgery or up to 27 weeks
|
Treatment Cohort - Change in cholesterol levels
Time Frame: Day 1 up to 4 weeks, up to 12 weeks and up to end of treatment or up to 24 weeks
|
Change from pre-neoadjuvant treatment in cholesterol levels
|
Day 1 up to 4 weeks, up to 12 weeks and up to end of treatment or up to 24 weeks
|
Treatment Cohort - Change in blood pressure
Time Frame: Day 1 up to 4 weeks, up to 12 weeks and up to end of treatment or up to 24 weekss
|
Change from pre-neoadjuvant treatment in blood pressure
|
Day 1 up to 4 weeks, up to 12 weeks and up to end of treatment or up to 24 weekss
|
Collaborators and Investigators
Sponsor
Collaborators
Investigators
- Principal Investigator: Matthew P Goetz, MD, Mayo Clinic
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Estimated)
Study Completion (Estimated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Estimated)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
- Skin Diseases
- Neoplasms
- Neoplasms by Site
- Breast Diseases
- Breast Neoplasms
- Physiological Effects of Drugs
- Molecular Mechanisms of Pharmacological Action
- Enzyme Inhibitors
- Antineoplastic Agents
- Hormones, Hormone Substitutes, and Hormone Antagonists
- Antineoplastic Agents, Hormonal
- Hormone Antagonists
- Aromatase Inhibitors
- Steroid Synthesis Inhibitors
- Estrogen Antagonists
- Goserelin
- Exemestane
Other Study ID Numbers
- ATOS-Z-201
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Breast Neoplasms
-
Emory UniversityEisai Inc.TerminatedBreast Cancer | Breast Neoplasms | Breast Tumors | Neoplasms, Breast | Cancer of the Breast | Tumors, BreastUnited States
-
Seagen Inc.CompletedTriple Negative Breast Neoplasms | Hormone Receptor Positive Breast Neoplasms | HER2 Positive Breast Neoplasms | HER2 Mutations Breast NeoplasmsUnited States
-
Innocrin PharmaceuticalCompletedBreast Cancer | Advanced Breast Cancer | Metastatic Breast Cancer | Triple Negative Breast Cancer | Male Breast Cancer | ER+ Breast Cancer | Cancer of the BreastUnited States
-
G1 Therapeutics, Inc.TerminatedBreast Cancer | Breast Neoplasm | Triple-Negative Breast Cancer | Triple-Negative Breast NeoplasmsUnited States, Bulgaria, Croatia, Slovenia, Serbia, Belgium, North Macedonia, Slovakia
-
Sidney Kimmel Cancer Center at Thomas Jefferson...Celgene CorporationTerminatedInflammatory Breast Cancer | Male Breast Cancer | Stage IV Breast Cancer | Recurrent Breast Cancer | HER2-negative Breast CancerUnited States
-
University of WashingtonNational Cancer Institute (NCI)CompletedInflammatory Breast Cancer | Male Breast Cancer | Stage II Breast Cancer | Stage IIIA Breast Cancer | Stage IIIB Breast Cancer | Stage IIIC Breast CancerUnited States
-
Dana-Farber Cancer InstituteConquer Cancer FoundationRecruitingBreast Cancer | Metastatic Breast Cancer | Triple Negative Breast Cancer | HER2-positive Breast Cancer | Inflammatory Breast Cancer | Hormone Receptor Positive Malignant Neoplasm of BreastUnited States
-
GlaxoSmithKlineCompletedNeoplasms, BreastUnited States, Spain, Israel, Canada, Belgium, United Kingdom, France, Tunisia
-
GlaxoSmithKlineCompletedNeoplasms, BreastUnited States, Canada, Germany, Spain, Taiwan, Belgium, Philippines, Israel, Hong Kong, Thailand, Pakistan, Russian Federation, Italy, Romania, China, France, Peru, United Kingdom, Czech Republic, Australia, Chile, Korea, Republic of and more
-
MedSIRHoffmann-La RocheCompletedAdvanced Breast Cancer | Metastatic Breast Cancer | Triple Negative Breast CancerSpain, France, United Kingdom, Germany, Italy
Clinical Trials on exemestane
-
Actavis Inc.Withdrawn
-
Jules Bordet InstituteNovartisCompleted
-
PfizerTerminated
-
PfizerCompletedPost Menopausal Women With Early Breast Cancer
-
Bristol-Myers SquibbCompletedBreast CancerCzech Republic, United States, Spain, United Kingdom, Ireland, Poland, France, Sweden
-
Veru Inc.WithdrawnMetastatic Breast CancerUnited States
-
Dalin Tzu Chi General HospitalCompletedHearing ImpairmentTaiwan
-
NCIC Clinical Trials GroupUNICANCER; Grupo Espanol de Investigacion del Cancer de MamaCompletedBreast CancerUnited States, France, Canada, Puerto Rico
-
PfizerCompleted
-
Roxane LaboratoriesCompleted